抗PD-(L)1免疫治疗在错配修复缺陷型转移性去势抵抗性前列腺癌中的疗效
这项国际多中心回顾性研究纳入93例错配修复缺陷(dMMR)的转移性去势抵抗性前列腺癌(mCRPC)患者,评估抗PD-(L)1单药治疗的疗效。结果显示客观缓解率46%,PSA下降≥50%者占60%,中位无进展生存期7.7个月,中位总生存期27.0个月。
要点
- dMMR mCRPC患者接受抗PD-(L)1单药治疗客观缓解率达46%。
- 中位无进展生存期7.7个月,3年无进展生存率26%。
- 两项及以上dMMR检测阳性者无进展生存期显著更长。
核心结论
- 抗PD-(L)1治疗在dMMR mCRPC患者中显示疗效,支持卫生部门考虑报销。
研究设计与样本
- 国际多中心回顾性研究,纳入2016年7月至2024年7月间93例dMMR mCRPC患者,中位年龄70岁(范围46-90)。
主要发现
- 可评估患者客观缓解率为46%(n=84;95%CI 35-58%)。
- 可评估患者中60%出现PSA下降≥50%(n=68;95%CI 48-72%)。
- 全队列中位无进展生存期为7.7个月(95%CI 5.3-12.4),1年、2年、3年无进展生存率分别为39%、27%、26%。
- 中位总生存期为27.0个月(95%CI 17.7-43.5)。
- 两项及以上dMMR检测阳性者的无进展生存期显著长于仅一项阳性者。
关键数值与推荐
- dMMR定义为免疫组化MMR蛋白缺失和/或MMR基因有害变异或MSI-H状态。
- dMMR判定依据:免疫组化结果37例(40%),MMR基因变异55例(59%),MSI-H表型64例(69%)。
临床怎么用
- 对mCRPC患者应进行dMMR/MSI-H检测以筛选抗PD-(L)1治疗获益人群。
- 多项dMMR检测阳性可能提示更优的无进展生存获益。
局限性
- 回顾性研究设计可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Up to 5% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbour loss-of-function alterations in mismatch repair genes (dMMR) resulting in microsatellite instability (MSI-H). Data on the efficacy of immune checkpoint inhibitors (ICIs) in dMMR mCRPC are limited, and reimbursement for these agents is not universally available. METHODS: We performed an international, multicentre, retrospective study to investigate the efficacy of anti-PD-(L)1 monotherapy in dMMR mCRPC. dMMR was defined as MMR protein loss on immunohistochemistry (IHC), and/or a deleterious alteration in an MMR gene or MSI-H status according to polymerase chain reaction analysis or next-generation sequencing. The primary endpoint was progression-free survival (PFS). KEY FINDINGS AND LIMITATIONS: Between July 2016 and July 2024, 93 patients with a median age of 70 yr (range 46-90) started anti-PD-(L)1 treatment. Patients were classified as dMMR on the basis of IHC results (n = 37, 40%), genomic alterations in MMR genes (n = 55, 59%), and/or an MSI-H phenotype (n = 64, 69%). Among evaluable patients according to Response Evaluation Criteria in Solid Tumours v1.1, the objective response rate was 46% (n = 84; 95% confidence interval [CI] 35-58%). A prostate-specific antigen decline ≥50% was observed in 60% of evaluable patients (n = 68; 95% CI 48-72%). Median PFS across the entire cohort was 7.7 mo (95% CI 5.3-12.4), with 1-yr, 2-yr, and 3-yr PFS rates of 39%, 27%, and 26%, respectively. Median overall survival was 27.0 mo (95% CI 17.7-43.5). PFS was significantly longer for patients with positive dMMR status on two or more tests than for patients with just one positive dMMR test. CONCLUSIONS AND CLINICAL IMPLICATIONS: These data confirm the efficacy of anti-PD-(L)1 therapy in patients with dMMR mCRPC and warrant consideration of reimbursement for anti-PD-(L)1 agents in dMMR mCRPC by health authorities.
引用
- van Wilpe S, Taha T, Rothmann EC, et al. Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40651931. doi:10.1016/j.euo.2025.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。